Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
McKinsey
Teva
Fish and Richardson
Queensland Health
Healthtrust

Generated: September 23, 2019

DrugPatentWatch Database Preview

Patent: 5,747,454

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 5,747,454
Title: Chromogranin peptides
Abstract:This invention relates to synthetic chromogranin A peptides, pharmaceutical compositions comprising these peptides, and uses of the peptides for treating hyperparathyroidism, and treating or preventing conditions associated with hyperparathyroidism such as parathyroid hyperplasia-associated renal failure, osteoporosis, and the like.
Inventor(s): Angeletti; Ruth Hogue (New Rochelle, NY), Russell; John (Bronx, NY)
Assignee: Albert Einstein College of Medicine of Yeshiva University (Bronx, NY)
Application Number:08/491,544
Patent Claims:see list of patent claims

Details for Patent 5,747,454

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 001 2015-01-23 ➤ Sign Up Albert Einstein College of Medicine of Yeshiva University (Bronx, NY) 2013-06-09 RX Orphan search
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 002 2015-01-23 ➤ Sign Up Albert Einstein College of Medicine of Yeshiva University (Bronx, NY) 2013-06-09 RX Orphan search
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 003 2015-01-23 ➤ Sign Up Albert Einstein College of Medicine of Yeshiva University (Bronx, NY) 2013-06-09 RX Orphan search
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 004 2015-01-23 ➤ Sign Up Albert Einstein College of Medicine of Yeshiva University (Bronx, NY) 2013-06-09 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Merck
Daiichi Sankyo
Chinese Patent Office
UBS
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.